TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22556050
Drug: Neuromuscular warm‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular warm‐up programme (15 minutes, targeting core stability, balance, and proper knee alignment, twice a week for one season)
Study: 19837764
Drug: (90)Y-ibritumomab tiuxetan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, as consolidation therapy after unlabeled rituximab 250 mg/m(2) on day -7
Study: 19837764
Drug: (90)Y-ibritumomab tiuxetan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, as consolidation therapy
Study: 11733394
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (0.5 or 2.0 mg/kg)
Study: 2886716
Drug: Hydrazine sulphate
Normalized name: benzoic acid 2-(2,4,6-trichlorophenyl)hydrazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrazine sulphate (60 mg three times daily for 30 days)
Study: 19260845
Drug: Maca dry
Normalized name: MACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca dry extract, 2400 mg
Study: 12893197
Drug: poly(L-lactide/glycolide) (PLG)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly(L-lactide/glycolide) (PLG) suture
Study: 27609188
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 8 ml/kg
Study: 8947448
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 14 ml/kg
Study: 1721597
Drug: Antibiotics combined
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics combined with immunomodulators
Study: 1721597
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with gamma-globulin
Study: 31512717
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W or 150 mg Q2W (depending on baseline LDL-C levels)
Study: 25234040
Drug: Endometrial infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial infusion of 500 IU of hCG diluted in ET media
Study: 25234040
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion of ET media (Control)
Study: 23104230
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D supplementation (1000 IU)
Study: 20951986
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) injection after endoscopic balloon dilation (EBD)
Study: 2450259
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine (5 mg/h during 85 min)
Study: 24165436
Drug: Therapist-aided exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-aided exposure treatment (n = 34)
Study: 20138810
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and letrozole (n=75)
Study: 20138810
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy and letrozole (n=75)
Study: 15834327
Drug: Preoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative epidural anesthesia with morphine (Group E)
Study: 15834327
Drug: Inhalation general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation general anesthesia with sevoflurane and intermittent intravenous administration of fentanyl (Group F)
Study: 10561813
Drug: Nifedipine OROS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine OROS 30 mg once daily (titrated to 60 mg if DBP > 90 mmHg)
Study: 10561813
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 5 mg once daily (titrated to 10 mg if DBP > 90 mmHg)
Study: 8722432
Drug: Fosinopril/Hydrochlorothiazide 10/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril/Hydrochlorothiazide 10/12.5 mg
Study: 8722432
Drug: Fosinopril/Hydrochlorothiazide 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril/Hydrochlorothiazide 20/12.5 mg
Study: 6891699
Drug: Estradiol-17 beta
Normalized name: ESTRADIOL 17-BETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-17 beta (200 micrograms, administered every other day for 10 days)
Study: 6891699
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg, administered every other day for 10 days)
Study: 6891699
Drug: Dihydrotestosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (200 mg, administered every other day for 10 days)
Study: 25132778
Drug: Ordinary daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary daily activities (control group)
Study: 22564148
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg weekly dosing after inadequate response to 40 mg eow dosing
Study: 22564148
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg eow dosing
Study: 28066879
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg weekly dosing
Study: 17198705
Drug: Conventional GnRH‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional GnRH‐agonist and recombinant FSH stimulation (IVO)
Study: 15987391
Drug: Remifentanil-based sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil-based sedation regime (initial dose 6 to 9 microg kg(‐1) h(‐1) titrated to response before the addition of midazolam)
Study: 15987391
Drug: Midazolam-based sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam-based sedation regime with fentanyl or morphine
Study: 12500172
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with appropriate hormone levels
Study: 7814081
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel 0.5 mg
Study: 19288084
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg)
Study: 3768242
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg) plus Ketanserin (20 mg)
Study: 29581212
Drug: 8-week Alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week Alert Program school curriculum delivered in weekly 1-hour lessons by trained classroom teachers.
Study: 21628604
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg alone
Study: 21628604
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg under steady‐state valproate (500 mg bid for 9 days)
Study: 20642579
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with depigmented polymerized birch pollen extract
Study: 26743539
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of purified Plasmodium falciparum sporozoites (n = 24)
Study: 26743539
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of purified Plasmodium falciparum sporozoites (n = 6)
Study: 19149819
Drug: AIDSVAX B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX B/E HIV vaccine
Study: 17495764
Drug: Oral alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha-lipoic acid (ALA) 600 mg
Study: 17495764
Drug: Oral alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha-lipoic acid (ALA) 1200 mg
Study: 17495764
Drug: Oral alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha-lipoic acid (ALA) 1800 mg
Study: 9870877
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 5, 10, or 20 mg/kg
Study: 28707217
Drug: 1% milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% milk (12 g carbohydrates)
Study: 28707217
Drug: apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: apple juice (29 g carbohydrates)
Study: 27011386
Drug: Lumbrokinase DLBS1033
Normalized name: LUMBROKINASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbrokinase DLBS1033 490 mg 3 times daily
Study: 18816008
Drug: Emotion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-focused therapy
Study: 10901907
Drug: Accelerated (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated (twice daily) radiotherapy
Study: 8196726
Drug: Cyclosporine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (4 mg per kilogram of body weight per day)
Study: 23866823
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg benralizumab (single-dose intravenous)
Study: 23866823
Drug: 100 or
Normalized name: Stalevo 100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 200 mg benralizumab (3 monthly subcutaneous doses)
Study: 15304046
Drug: Heparin (9000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (9000 IU of four heparins of different mol. wt distributions)
Study: 11402638
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 8 mg + Oral Contraceptive (OC)
Study: 11402638
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (P) + Oral Contraceptive (OC)
Study: 7904085
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with disease-modifying antirheumatic drugs (DMARDs), specific details on dosage and duration not available.
Study: 25772594
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol therapy
Study: 16920898
Drug: Amlodipine besylate/atorvastatin
Normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate/atorvastatin calcium combination tablet (10/80 mg; n = 62)
Study: 16920898
Drug: Amlodipine besylate/atorvastatin
Normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate/atorvastatin calcium combination tablet (5/10 mg; n = 64)
Study: 15494466
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT; conjugated estrogens, 0.625 mg/d; trimonthly medroxyprogesterone acetate, 5 mg/d for 13 d)
Study: 9155120
Drug: Gelseal (g-G0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelseal (g-G0, n = 7)
Study: 9155120
Drug: Hemashield (g-H0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemashield (g-H0, n = 8)
Study: 9155120
Drug: Hemashield (g-H,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemashield (g-H, n = 7)
Study: 9155120
Drug: Gelseal (g-G,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelseal (g-G, n = 5)
Study: 9155120
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (g-G and g-H)
Study: 9155120
Drug: Gelseal (g-G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelseal (g-G)
Study: 9155120
Drug: Hemashield (g-H)
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemashield (g-H)
Study: 8399497
Drug: 0.5% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podophyllotoxin lotion
Study: 8399497
Drug: 25% podophyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% podophyllin solution
Study: 3527643
Drug: Horse-chestnut seed
Normalized name: horse chestnut seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-chestnut seed extract (Venostasin retard) 600 mg (two capsules of 50 mg aescin each)
Study: 3527643
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking capsule)
Study: 22018188
Drug: Prednisone 3
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 3 mg/day
Study: 19360864
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with low-dose tenecteplase (10 mg)
Study: 19360864
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with low-dose tenecteplase
Study: 16297507
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients without systemic steroids for the previous 3 months, treated with steroids for 4 weeks
Study: 16297507
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients with chronic steroid treatment both before and during the investigation
Study: 16297507
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients without systemic steroids for the previous 3 months, vaccinated after 4 weeks of steroid treatment
Study: 11140430
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 microg by inhalation via Diskhaler
Study: 11140430
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 microg by inhalation via Diskus
Study: 11140430
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 microg twice daily via Diskhaler
Study: 3652469
Drug: Progesterone (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (50‐100 mg/d for 7 d)
Study: 3652469
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg/h for 8 h) after progesterone treatment
Study: 31978434
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg orally 8 hourly up to 150 mg
Study: 27591784
Drug: Ophthalmic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic artery (OA) blood flow measurement using ultrasound color doppler imaging (CDI)
Study: 26971823
Drug: Topical ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ethyl chloride
Study: 26971823
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water aerosol spray)
Study: 24387624
Drug: 60-minute loading
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute loading infusion of magnesium sulphate (4 g over 60 minutes)
Study: 24387624
Drug: 20-minute loading
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute loading infusion of magnesium sulphate (4 g over 20 minutes)
Study: 24387624
Drug: 60-minute loading
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute loading infusion of magnesium sulphate
Study: 24387624
Drug: 20-minute loading
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute loading infusion of magnesium sulphate
Study: 21717444
Drug: Cenersen inhibitors
Normalized name: Cenersen
DrugBank: Cenersen (DB15455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenersen inhibitors (acetaminophen and/or high dose antioxidants)
Study: 19608835
Drug: Extended perineural
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended perineural ropivacaine infusion (n = 24)
Study: 17499389
Drug: Alcohol-based spray
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-based spray sunscreen
Study: 11864853
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fat diet (sunflower oil + 4-4.5 g fish oil/d)
Study: 11332869
Drug: alpha‐dihydroergocryptine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐dihydroergocryptine (10 mg twice daily)
Study: 11279920
Drug: flunarizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunarizine (5 mg once daily)
Study: 7778155
Drug: Aminosidine 12
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Study: 7778155
Drug: Aminosidine 12
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Study: 7778155
Drug: Aminosidine 12
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Study: 7778155
Drug: Aminosidine 6
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Study: 7778155
Drug: Aminosidine 6
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Study: 7778155
Drug: Aminosidine 6
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Study: 7778155
Drug: Overall success
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall success rate with aminosidine 12 mg/kg/d
Study: 7778155
Drug: Overall success
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall success rate with aminosidine 6 mg/kg/d
Study: 7778155
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of aminosidine 12 mg/kg/d vs 6 mg/kg/d
Study: 6162348
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream applied under occlusive dressing for 60 minutes
Study: 29234808
Drug: Levothyroxine (25-μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (25-μg/d or 50-μg/d, titrated according to TSH levels during pregnancy)
Study: 29234808
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no levothyroxine treatment)
Study: 26251480
Drug: Monthly health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly health education meetings and monthly calls from the study coordinator
Study: 14742609
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of quetiapine
Study: 14742609
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of quetiapine (open label phase)
Study: 11851736
Drug: Lower leg
Normalized name: CAPSAICIN 0.18 g in 100 g TOPICAL CLOTH [Nufabrx Lower Leg Sleeve]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower leg casting prior to BTX‐A injections
Study: 11851736
Drug: Casting immediately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casting immediately after BTX‐A injections
Study: 9870539
Drug: Implant prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant prostheses
Study: 2680476
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (plateau insulin concentration 50‐55 mU/l)
Study: 21884956
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all prescribed hypertension medications upon awakening
Study: 22158066
Drug: Ingesting ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting ≥1 hypertension medication at bedtime
Study: 22152013
Drug: High-dose erythropoiesis-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose erythropoiesis-stimulating agents (ESA) (≥ 1 μg/kg/week)
Study: 22152013
Drug: Usual-dose erythropoiesis-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose erythropoiesis-stimulating agents (ESA) (< 1 μg/kg/week)
Study: 22152013
Drug: Higher ESA
Normalized name: esafoxolaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher ESA dose (per μcg/kg/week)
Study: 22152013
Drug: High-dose erythropoiesis-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose erythropoiesis-stimulating agents (ESA)
Study: 15156393
Drug: Bupivacaine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 80 mg in 25 cc of saline
Study: 11305844
Drug: Generic clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic clozapine (Zenith Goldline Pharmaceuticals)
Study: 11305844
Drug: Clozaril (Novartis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozaril (Novartis Pharmaceuticals)
Study: 9438889
Drug: Gravity flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gravity flow administration of local anesthetic (Group 1)
Study: 9438889
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection (Group 2)
Study: 7705775
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg three times daily for 4 weeks)
Study: 2650694
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with fish oil providing about 3.2 g n-3 fatty acids per day
Study: 31867715
Drug: Carbetocin (ED90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (ED90 estimated as 62.9 μg using truncated Dixon and Mood method)
Study: 31867715
Drug: Carbetocin (ED90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (ED90 estimated as 68 μg using isotonic regression method)